Home>Topics>Companies>Abbott Laboratories

Abbott Laboratories ABT

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Fitch Downgrades Abbotts's L-T IDR to 'A'; Outlook Revised to Stable

      Headlines

      Mon, 18 May 2015

      following statement was released by the rating agency) CHICAGO, May 18 (Fitch) Fitch Ratings has downgraded Abbott Laboratories ' (Abbott) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook

    2. UPDATE 1-Abbott says its payoff from Mylan deal surged

      Headlines

      Wed, 22 Apr 2015

      April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

    3. CORRECTED-Abbott says payoff from Mylan deal surges, as Mylan shares leap

      Headlines

      Wed, 22 Apr 2015

      April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion...

    4. UPDATE 1-Abbott profit beats expectations, sales of branded generics jump

      Headlines

      Wed, 22 Apr 2015

      April 22 (Reuters) - Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.

    5. Abbott Labs profit from continuing operations more than doubles

      Headlines

      Wed, 22 Apr 2015

      April 22 (Reuters) - Abbott Laboratories ' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions.

    6. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

      Commentary

      Tue, 21 Apr 2015

      Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense

    7. Complexities of Eye Care Drive Strong Moats

      Headlines

      Fri, 6 Mar 2015

      example, Novartis has an estimated 60% market share, yet surgical sales make up only about 6% of total company sales. At Abbott ABT and Valeant, the next-largest players, ophthalmology surgical products account for 5%-7% of total company sales

    8. Global Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

      Commentary

      Fri, 27 Feb 2015

      in the global home healthcare market that have been profiled in the report include 3M Health Care, Bayer AG, Abbott Laboratories , Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services, Inc

    9. Compelling Financial Benefit in Valeant's Latest Buy

      Headlines

      Fri, 27 Feb 2015

      in ophthalmology, since Valeant will face a much more concentrated market and larger competitors, such as Novartis NVS , Abbott ABT , and Johnson & Johnson JNJ , but we still believe there will still be attractive opportunities for Valeant. The market is

    10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

      Video Reports

      Fri, 2 Jan 2015

      methodology. If we go back to several years ago when we first started this, firms that ranked very well like [TICKER:ABT] Abbott ( ABT ) and [TICKER:NVS] Novartis (NVS), following two years of their high rankings, they posted 40% gains. A lot of this

      Abbott ABT found at 1:10

      ago when we first started this, firms that ranked very well like [TICKER:ABT] Abbott ( ABT ) and [TICKER:NVS] Novartis (NVS), following two years of their high rankings, they posted 40% gains. A lot of this had to do with
    « Prev12345Next »
    Content Partners